Research Progress on Anti-EGFR Rechallenge for the Third-Line Therapy of Metastatic Colorectal Cancer
The epidermal growth factor receptor(EGFR)monoclonal antibody is an effective first-line drug for metastatic colorectal cancer patients.However,the emergence of acquired resistance after anti-EGFR therapy limits the use of EGFR inhibitors in the sustained treatment of metastatic colorectal cancer.Based on molecular biology research,the anti-EGFR rechallenge strategy has potential activity in clinical management of RAS/BRAF wild-type metastatic colorectal cancer pa-tients after second-line treatment.This paper reviews the efficacy and related toxicity of the anti-EGFR rechallenge strategy in the third-line treatment of metastatic colorectal cancer,as well as the prediction factors for efficay,to provid a new perspective for clinical practice and scientific re-search.
NETL
NSTL
万方数据
